MedTrace Logo

Quality Improvement PrecivityAD Clinician Survey (QUIP I)

NCT05477056 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 366

Last updated 2025-02-20

No results posted yet for this study

Summary

There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.

Conditions

Interventions

OTHER

PrecivityAD blood test

Clinician Survey post receipt of PrecivityAD blood test result

Sponsors & Collaborators

Principal Investigators

  • Tim West, Ph.D · C2N

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-10-06
Completion
2022-10-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477056 on ClinicalTrials.gov